Meta-analysis for Discovering Rare-Variant Associations: Statistical Methods and Software Programs  by Tang, Zheng-Zheng & Lin, Dan-Yu
ARTICLE
Meta-analysis for Discovering Rare-Variant Associations:
Statistical Methods and Software Programs
Zheng-Zheng Tang1 and Dan-Yu Lin2,*
There is heightened interest in using next-generation sequencing technologies to identify rare variants that influence complex human
diseases and traits. Meta-analysis is essential to this endeavor because large sample sizes are required for detecting associations with rare
variants. In this article, we provide a comprehensive overview of statistical methods for meta-analysis of sequencing studies for discov-
ering rare-variant associations. Specifically, we discuss the calculation of relevant summary statistics from participating studies, the con-
struction of gene-level association tests, the choice of transformation for quantitative traits, the use of fixed-effects versus random-effects
models, and the removal of shadow association signals through conditional analysis.We also show that meta-analysis based on properly
calculated summary statistics is as powerful as joint analysis of individual-participant data. In addition, we demonstrate the performance
of differentmeta-analysismethods by using both simulated and empirical data.We then compare fourmajor software packages for meta-
analysis of rare-variant associations—MASS, RAREMETAL, MetaSKAT, and seqMeta—in terms of the underlying statistical methodology,
analysis pipeline, and software interface. Finally, we present PreMeta, a software interface that integrates the fourmeta-analysis packages
and allows a consortium to combine otherwise incompatible summary statistics.Introduction
Advances in next-generation sequencing technologies pro-
vide an unprecedented opportunity to discover rare vari-
ants and evaluate their contributions to disease risk and
trait variation. For the analysis of rare-variant associations,
it is customary to aggregate mutation information across
several variant sites within a gene to enrich association sig-
nals and to reduce the penalty resulting from multiple
testing. The most common gene-level association test is
the burden test, which creates a burden score for each
study subject by collapsing the variants with minor allele
frequencies (MAFs) below a certain threshold and relates
that burden score to the trait of interest.1–4 As an exten-
sion, the combined multivariate and collapsing (CMC)
method divides the variants into subgroups according to
their MAFs and collapses the variants within each sub-
group.5 A second approach is the variable-threshold (VT)
method, which performs a burden test at each MAF
threshold and chooses the threshold that yields the largest
test statistic.4,6 A third approach is the variance-compo-
nent (VC) test, such as the sequence kernel association
test (SKAT), which is aimed at detecting variants with
opposite effects within a gene.7–9 A related approach is
SKAT-O, which is a weighted sum of the burden and
SKAT statistics.10
Even with aggregation of association signals across mul-
tiple variant sites, gene-level tests have limited power to
detect rare-variant associations because only a small frac-
tion of study subjects carry any mutation within a gene,
and there is a high background rate of neutral variation
even in a ‘‘causal’’ gene. Indeed, few major findings have
emerged from recent sequencing efforts. It is now widely1Department of Biostatistics, Vanderbilt University School of Medicine, Nas
Carolina, Chapel Hill, NC 27599-7420, USA
*Correspondence: lin@bios.unc.edu
http://dx.doi.org/10.1016/j.ajhg.2015.05.001. 2015 by The American Societ
Threcognized that large-scale meta-analysis is required for
discovering causal rare variants. Thus, a growing number
of consortia are created to conduct meta-analysis of
sequencing studies, as was done for genome-wide associa-
tion studies (GWASs).
It is more challenging to perform meta-analysis for rare
variants in sequencing studies than for common variants
in GWASs. First, effect estimates might be unstable or
even undefined when only a small number of subjects
carry anymutation, such that the familiar inverse-variance
estimator for GWAS meta-analysis is not suitable for rare-
variant meta-analysis. Second, VT and VC tests are
multivariate in nature, such that meta-analysis requires
multivariate summary statistics (i.e., the components of
the test statistic and their covariance matrix). Third,
participating studies might adopt different gene-level tests
or generate different types of summary statistics, such that
the results cannot be directly combined. Finally, rare vari-
ants tend to be population specific (i.e., present in some
populations but not in others), such that different studies
might contribute different sets of variants to a given gene-
level test and thus show different strengths of the gene-
level association even when each variant has the same
effect size among studies.
Recently, several research groups published meta-anal-
ysis methods for rare-variant association tests.11–17 They
all considered quantitative traits; some considered binary
traits and survival data. Not all groups implemented all
the aforementioned gene-level association tests. A fraction
of the methods can handle family data or extreme-trait
sampling. Most methods are based on fixed-effects (FE)
models, which assume that the genetic effects are the
same in all participating studies; some are based onhville, TN 37203, USA; 2Department of Biostatistics, University of North
y of Human Genetics. All rights reserved.
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random-effects (RE) models, which allow effect sizes to
vary across studies. The similarities and differences among
various methods have not been well appreciated.
In this article, we provide a unified framework for per-
forming meta-analysis of rare-variant associations. Our
framework is general enough to encompass all existing
methods and facilitate a comprehensive comparison.
First, we discuss the calculation of relevant summary
statistics from participating studies, the construction of
appropriate gene-level association tests from the summary
statistics, the choice of transformation for quantitative
traits, the merits of FE versus RE models, the removal of
shadow association signals through conditional analysis,
and the relative efficiency of using summary statistics
versus individual-participant data. Then, we report simula-
tion results that demonstrate key differences among
various methods. In addition, we provide an illustration
with empirical data from the NHLBI Exome Sequencing
Project (ESP).18,19
The aforementioned meta-analysis methods for rare-
variant associations have been implemented in four
major software packages: MASS,11,12 MetaSKAT,13
RAREMETAL,14,15 and seqMeta.16,17 Each package consists
of two separate steps: (1) calculating summary statistics for
each sequencing study and (2) combining summary statis-
tics to perform gene-level association tests (i.e., actual
meta-analysis). Several questions arise when these pack-
ages are applied to actual studies, especially in a con-
sortium setting:
(1) Are the summary statistics calculated the same way
in different software packages?
(2) What are the main differences in the meta-analysis
methods that are implemented in different pack-
ages?
(3) Can the summary statistics from one package be
used for performing meta-analysis in another
package?
To answer these questions, we carefully examined the
four software packages and carried out various compari-
sons. Because we found that the answer to the last question
was negative, we developed a special software interface
that allows the summary statistics generated from any
package to be used in any other package for meta-analysis.
This development greatly facilitates meta-analysis in a
large consortium, especially when different investigators
use different meta-analysis packages. In addition, it elimi-
nates the need to re-calculate summary statistics when in-
vestigators join new consortia.Material and Methods
Summary Statistics
The first step of any meta-analysis is to obtain summary statistics
from participating studies. The form of summary statistics de-
pends on the type of association tests to be performed. In earlier36 The American Journal of Human Genetics 97, 35–53, July 2, 2015days, Wald statistics were used for burden and VT tests. That strat-
egy, however, is problematic for rare variants because the effect
estimates can be unstable when only a small number of subjects
carry any mutation. For example, the log-odds ratio is undefined
if there are no mutations in either the case or control group. Score
statistics are statistically more accurate and numerically more sta-
ble than Wald and likelihood-ratio statistics, especially for binary
traits.4 At present, score statistics are used almost exclusively for
association tests with rare variants, whether the analysis involves
a single study or multiple studies. We describe below how to calcu-
late score statistics in a study.
Variant-Level Statistics
Suppose that we are interested in m rare variants within a
gene. We represent the genotypes by G ¼ ðg1; :::; gmÞT, where gj
is the number of minor alleles at the jth variant site. Let Y
denote the trait of interest, which can be continuous or discrete,
and let X denote a set of covariates (e.g., demographic variables,
principal components for ancestry, and environmental factors)
plus the unit component. We relate Y to G and X through a
generalized linear model by specifying the conditional density
function of Y given G and X as
exp
(
Y

bTG þ gTX bbTG þ gTX
aðfÞ þ cðY;fÞ
)
; (Equation 1)
where b ¼ ðb1;.;bmÞT and g are regression parameters, f is a
dispersion parameter, and a, b, and c are specific functions. We
will use the first and second derivatives of b, which are denoted
by b0 and b0 0, respectively. For the linear regression model with er-
ror variance s2, we have aðfÞ ¼ s2, bðzÞ ¼ ð1=2Þz2, b0ðzÞ ¼ z, and
b00ðzÞ ¼ 1. For the logistic regression model, we have aðfÞ ¼ 1,
bðzÞ ¼ logð1þ ezÞ, b0ðzÞ ¼ ez=ð1þ ezÞ, and b00ðzÞ ¼ ez=ð1þ ezÞ2.
For a study with n unrelated subjects, the data consist of
(Yi, Gi, Xi) (i ¼ 1,., n). The score statistic for testing the null hy-
pothesis, H0: b ¼ 0, is
U ¼ 1
a
bf X
n
i¼1

Yi  b0
bgTXiGi;
where bg and bf are the restricted maximum-likelihood estima-
tors (MLEs) of g and f, respectively, under H0. For the
linear model, bg ¼ ðPni¼1XiXTi Þ1Pni¼1YiXi, and aðbfÞ ¼ bs2 ¼
n1
Pn
i¼1ðYi  bgTXiÞ2. Under H0, U is asymptotically m-variate
normal with mean 0 and covariance matrix
V ¼ 1
a
bf
"Xn
i¼1
b00
bgTXiGiGTi 
(Xn
i¼1
b00
bgTXiGiXTi
)
3
(Xn
i¼1
b00
bgTXiXiXTi
)1(Xn
i¼1
b00
bgTXiXiGTi
)#
;
which is the (profile) information matrix for b evaluated at b ¼ 0,
g ¼ bg, and f ¼ bf.
Quantitative Traits
For quantitative traits,
U ¼ 1bs2 X
n
i¼1

Yi  bgTXiGi;
and
V ¼ 1bs2
8<:Xn
i¼1
GiG
T
i 
 Xn
i¼1
GiX
T
i
! Xn
i¼1
XiX
T
i
!1 Xn
i¼1
XiG
T
i
!9=;:
Note that U is normalized by the residual variance bs2. Without
this normalization, the ‘‘score statistic’’ and ‘‘informationmatrix,’’
respectively, take the forms
Uy ¼
Xn
i¼1

Yi  bgTXiGi
and
Vy ¼ bs2
8<:Xn
i¼1
GiG
T
i 
 Xn
i¼1
GiX
T
i
! Xn
i¼1
XiX
T
i
!1 Xn
i¼1
XiG
T
i
!9=;:
Clearly, U ¼ Uy=bs2; and V ¼ Vy=bs4: If association tests are per-
formed for a single study, then the use of U and V is equivalent
to the use ofUy andVy because bs2 is just a constant. In meta-anal-
ysis, we first combine the score statistics and information matrices
across different studies and then perform association tests. In that
case, the use of U and V is not equivalent to the use of Uy and Vy
unless the residual variances are the same among studies. If the
study populations differ in terms of ethnicity, gender, age, or envi-
ronment, then their residual variances are most likely different.
The use of un-normalized score statistics has undue influence on
the power of meta-analysis, as will be shown later.
Gene-Level Tests
For burden and VT tests, we create a burden score s for each subject
by collapsing the variants below a given MAF threshold and relate
the burden score to the trait of interest. Specifically, we replace the
linear predictor bTG þ gTX in Equation 1 with bsþ gTX; where
b represents the effect of the burden score. Under the additive
mode of inheritance, the burden score is a weighted sum of the
mutation counts, such that
s ¼
Xm
j¼1
cjgj; (Equation 2)
where cj is a specific weight for the j
th variant. For the simple
burden test, cj ¼ 1 if the MAF of the jth variant, denoted by
MAFj, is less than a certain threshold (e.g., 1% or 5%), and cj ¼ 0
otherwise.1,3,4 For the Madsen and Browning (MB) weighting
scheme,2 cj ¼ 1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MAFjð1MAFjÞ
p
: In the original MB test, MAFj
is estimated from the control group; today, it is customary to use
pooled estimates, which are numerically more stable and permit
normal approximation of the score statistic.4
Let u* and v* denote the score statistic and information matrix,
respectively, for testing the null hypothesis that b ¼ 0. It is easy to
show that u*¼ CTU and v* ¼ CTVC, where C ¼ (c1,., cm)T.4,20 The
score statistics for testing burden scores at different thresholds and
their covariances can also be obtained by transformation of U and
V, respectively. Specifically, the covariance between CTU and ~C
T
U
isCTV ~C.4,20 Furthermore, SKATstatistics are simple functions ofU
and V.9 Thus, it is only necessary to collect variant-level statistics,
U and V, from participating studies.
Under the dominant mode of inheritance, the burden score in-
dicates the presence of any mutation at the m variant sites.1,5 In
this case, Equation 2 no longer holds, and we cannot directly
construct u* from U. Thus, each study needs to provide summary
statistics at the burden-score level for each burden test.
If the MAFs of the aggregated variants are very small, the addi-
tive and dominant versions of the burden score will be similar
because the chance that any subject carries more than one muta-
tion is extremely low. If we collapse common variants (as in the
CMC test) or imputed genotypes, then the two versions of the
burden score can be quite different.ThConditional Analysis
Because of linkage disequilibrium (LD), one or more causal vari-
ants can result in spurious association signals at nearby variants.
Conditional analysis can remove the shadow signals by deter-
mining whether the signals remain after adjusting for nearby
signals. For conditional analysis, we decompose the vector of ge-
notypes G into two subsets—G1 pertains to the causal SNPs that
we wish to adjust for, andG2 pertains to the variants whose effects
we wish to test—such that the linear predictor in Equation 1 be-
comes bT1G1 þ bT2G2 þ gTX: Let ~U2 denote the score statistic for
testing the null hypothesis that b2 ¼ 0. To directly calculate this
score statistic and the corresponding information matrix, ~V2, we
would need to fit the reduced model with the linear predictor
bT1G1 þ gTX for each choice of G1 so as to obtain the restricted
MLEs ~b1, ~g, and ~f. This would be very cumbersome and restrictive,
especially in a large consortium. Fortunately, it is possible to deter-
mine ~U2 and ~V2 without fitting this model, as explained below.
We partitionU andV to conformwith the partition ofG intoG1
and G2, such that
U ¼

U1
U2

and V ¼

V11 V12
V21 V22

:
We derive the following results in Appendix A:
~U2z
a
bf
a

~f
 U2 V21V111U1; (Equation 3)
and
~V2z
a
bf
a

~f
 V22 V21V111V12: (Equation 4)
For linear regression, the approximations are exact, and að~fÞ ¼
~s2 ¼ bs2ð1 n1UT1V111U1Þ. For logistic regression, the approxima-
tions are reasonable, and að~fÞ ¼ aðbfÞ ¼ 1.
The above results show that the summary statistics for condi-
tional analysis can be constructed from the variant-level summary
statistics U and V for unconditional analysis. Thus, we can
perform conditional analysis without actually fitting the condi-
tional model. This remarkable fact was discovered by Yang
et al.21 and Liu et al.14 in the special case of linear regression
without covariates forWald statistics and un-normalized score sta-
tistics, respectively. Although the formulas are simple, the deriva-
tion is not, as is evident in Appendix A. It should be emphasized
that the equations are not exact outside of linear regression,
such that the corresponding test statistics might differ from the
ones that are calculated directly.
Family Studies
We consider a study of n (potentially) related subjects. Define
Y ¼
24Y1«
Yn
35; G ¼
24GT1«
GTn
35; andX ¼
24XT1«
XTn
35:
For quantitative traits, it is natural to specify the linear mixed
model
Y ¼ GbþXgþ dþ e;
where b and g are vectors of regression parameters, d is an n-variate
normal random vector withmean 0 and covariancematrix hs2F, e
is an n-vector of independent zero-mean normal random variables
with variances ð1 hÞs2, F is twice the kinship matrix, s2 is thee American Journal of Human Genetics 97, 35–53, July 2, 2015 37
trait variance, and h is the heritability. The covariance matrix of Y
is s2U, where U ¼ hFþ ð1 hÞI; and I is the n 3 n identify
matrix.
The score statistic for testing H0: b ¼ 0 can be written as
U ¼ 1bs2GT bU1ðY X bgÞ;
where bg ¼ ðXT bU1XÞ1ðXT bU1YÞ, bU ¼ bhFþ ð1 bhÞI , and bs2
and bh are the restricted MLEs of s2 and h, respectively, under H0.
The corresponding information matrix V takes the form
V ¼ 1bs2
n
GT bU1G GT bU1XXT bU1X1XT bU1Go:
It is reasonable to assume that the estimation of h is not sensi-
tive to the linear predictor. By multiplying U1=2 by Y, we end up
with a vector of independent observations. Thus, the condi-
tional-analysis formulas given in Equations 3 and 4 apply to fam-
ily data.Meta-analysis
The two major approaches to meta-analysis are the FE and RE
models. Under the FE model, the effects of each variant are
assumed to be the same among all participating studies; under
the RE model, the effects are allowed to vary among studies. For
gene-level associations, the effects of individual variants can
vary considerably within a study and across studies.
If the study populations are different, then the effects of a
gene on a trait will most likely vary across studies because (1)
the gene might interact with other functional variants that
have different frequencies among populations and (2) environ-
mental, dietary, or lifestyle factors might modify the influence
of the gene.12,22 The heterogeneity of genetic associations might
also be caused by differences in the definition or measurement of
the trait across studies and by differences in the sequencing plat-
form, quality-control criteria, or gene annotation.12,22 In addi-
tion, association analysis of rare variants is conducted at the
gene level. Because rare variants tend to be population spe-
cific,18 different studies might contain different rare variants for
the same gene, such that the strength of the gene-level associa-
tion might be different among studies even if the allelic effects
are homogeneous.
Despite the prevalence of heterogeneity, FE models have been
used almost exclusively in genetic association studies because
they tend to be more powerful than RE models. Han and Eskin23
showed that the loss of power under RE models is actually due
to inappropriate choice of test statistics. Traditional RE methods
are designed to detect the mean effect while allowing heterogene-
ity.24 This is not the most relevant framework for genetic associa-
tion studies because the presence of heterogeneity implies the
existence of non-zero effects in at least some studies. Thus, Han
and Eskin23 proposed a test of the joint null hypothesis that there
is nomean effect and no heterogeneity; their test is more powerful
than the FE counterpart when genetic associations are heteroge-
neous. Han and Eskin23 considered only single-variant analysis
for common SNPs in GWASs, but their approach has been
extended to gene-level tests for rare variants.12,13 We will present
both FE and RE methods and compare their performance analyti-
cally and numerically.
Suppose that there are K independent studies. For k¼ 1,., K, let
bk and b

k denote the values of b and b
, respectively, for the kth
study. In addition, let Uk denote the score statistic for testing the38 The American Journal of Human Genetics 97, 35–53, July 2, 2015null hypothesis that bk ¼ 0, and let Vk be the corresponding
information matrix. We show below how to use Uk and Vk to
construct the FE and RE versions of the burden, VT, SKAT, and
SKAT-O tests.
FE Models
Under FE models, b1 ¼ b2 ¼. ¼ bK ¼ m, where m represents
the common effects of the m variants across the K studies. We
take the summations of Uk and Vk over the K studies to obtain
the overall score statistic (Um) and information matrix (Vm),
respectively:
Um ¼
XK
k¼1
Uk andVm ¼
XK
k¼1
Vk:
Under the null hypothesis that m ¼ 0, the statisticUm is asymptot-
ically m-variate normal with mean 0 and covariance matrix Vm.
For the burden test, the FE model assumes that b1 ¼
b2 ¼. ¼ bK ¼ m, where m is the common effect of the burden
score. Let uk and v

k denote the score statistic and information
matrix, respectively, for testing the null hypothesis that bk ¼ 0.
Write um ¼
PK
k¼1u

k and vm ¼
PK
k¼1v

k . The test statistic takes
the form
FE-burden ¼ u
2
m
vm
;
which is referred to the c21 distribution. Under the additive mode
of inheritance, um and vm can be constructed from Um and Vm,
respectively, as follows: um ¼ CTUm and vm ¼ CTVmC for any
set of weights C. Under the dominant mode of inheritance, um
and vm need to be calculated directly from the burden scores.
For the VT method, we perform a burden test at each observed
MAF threshold and choose the threshold that produces the most
significant result. Thus, the test statistic is expressed as
FE-VT ¼ max
j¼1;.;J

FE-burdenj

;
where J is the total number of MAF thresholds, and FE-burdenj
is the FE-burden at the jth threshold. The p value can be deter-
mined analytically by the joint distribution of um at the J
thresholds; under the additive mode of inheritance, this joint dis-
tribution is a transformation of the multivariate normal distribu-
tion of Um.
4,20
SKAT is a VC test aimed at detecting bi-directional effects
among them variants.9 For this test, the mean of the variant-level
effects m is assumed to be an m-variate random vector with
mean 0 and covariance matrix twW, where tw is the variance
component indicating the within-study variation of the variant
effects and W ¼ diagfw21 ;.;w2mg is a pre-specified diagonal
matrix in which the element wj represents the within-study
weight for the jth variant. Clearly, tw ¼ 0 if and only if m ¼ 0.
The score statistic for testing the null hypothesis that tw ¼ 0 takes
the form
FE-SKAT ¼ UTmWUm:
The p value is determined by the mixture c21 distributionPm
j¼1ljc
2
1;j; where lj is the j
th eigenvalue of V1=2m WV
1=2
m and
c21;1;.;c
2
1;m are independent c
2
1 random variables.
9
SKAT-O, an extension of SKAT, allows a pairwise correlation r
among the m components of m. The test statistic takes the form
FE-SKAT-O ¼ ru2m þ ð1 rÞFE-SKAT;
which is a weighted sum of the squared score statistic for the
burden test with cj¼ wj (j¼ 1,.,m) and the SKAT statistic. Clearly,
FE-SKAT-O reduces to FE-burden and FE-SKAT when r ¼ 1 and 0,
respectively. In practice, the value of r is unknown and is adap-
tively chosen to produce the most significant result. The p value
of FE-SKAT-O can be obtained by a one-dimensional numerical
integration.10
RE Models
For the burden test, the RE model assumes that bk ¼ m þ xk,
where m represents the mean effect of the burden score across
studies, and xk represents the deviation of the effect of the k
th
study from the mean. We assume that xk is a zero-mean random
variable with variance t, where t measures the between-study
heterogeneity of the effects of the burden score. The statistic
for testing the joint null hypothesis that m ¼ 0 and t ¼ 0 takes
the form12
RE-burden ¼ FE-burden þ ðut  vmÞ
2
2
PK
k¼1v
2
k
;
where ut ¼
PK
k¼1u
2
k . The VT test statistic is defined as
RE-VT ¼ max
j¼1;.;J

RE-burdenj

;
where RE-burdenj is the RE-burden at the j
th MAF threshold.12
For SKAT, we assume that bk ¼ mþ xk, where m represents the
mean effects of the m variants across studies, and xk represents
the deviations of the effects of the kth study from the mean
effects. As in FE-SKAT, we assume that m is a zero-mean random
vector with covariance matrix twW. In addition, we assume
that xk is a zero-mean random vector with covariance matrix
tbB, where tb is a scalar indicating the between-study variation
of the effects, and B ¼ diagfb21;.; b2mg is a pre-specified diagonal
matrix in which bj represents the between-study weight for the j
th
variant.
Two versions of SKAT have been proposed under the RE model.
Het-SKAT13 tests the null hypothesis that tb ¼ 0 given tw ¼ 0. The
test statistic can be written as
Het-SKAT ¼
XK
k¼1
UTkBUk:
RE-SKAT12 tests the joint null hypothesis that tw ¼ 0 and tb ¼ 0,
and the test statistic takes the form
RE-SKAT ¼ 	Utw Utb 
V1t UtwUtb

;
where Utw ¼ ð1=2ÞFE-SKAT ð1=2ÞtraceðVmWÞ, Utb ¼ ð1=2ÞHet-
SKAT ð1=2ÞtraceðVmBÞ, and
Vt ¼ 1
2
24 traceðVmWVmWÞ traceXKk¼1VkWVkB
trace
XK
k¼1VkBVkW

trace
XK
k¼1VkBVkB
 35;
which is the covariance matrix of ðUtw ;Utb Þ. Het-SKAT is aimed at
detecting heterogeneity under the assumption of no mean effects,
whereas RE-SKAT is aimed at detecting both mean effects and het-
erogeneity. As such, the former tends to bemore powerful than the
latter when the mean effects are zero but less powerful when the
mean effects are not zero.
As an RE version of SKAT-O, RE-SKAT-O12 allows a within-study
pairwise correlation r among the m components of m and a be-Thtween-study pairwise correlation r among the m components of
xk, such that
W ¼
26664
w21 w1w2r . w1wmr
w2w1r w
2
2 . w2wmr
« « 1 «
wmw1r wmw2r . w
2
m
37775;
B ¼
266664
b21 b1b2r . b1bmr
b2b1r b
2
2 . b2bmr
« « 1 «
bmb1r bmb2r . b
2
m
377775:
By replacingW and B in RE-SKATwith the above twomatrices, we
obtain
Utw ¼
1
2
n
ru2m þ ð1 rÞFE-SKAT
o
 1
2
traceðVmWÞ
and
Utb ¼
1
2

ru2t þ ð1 rÞHet-SKAT
 1
2
traceðVmBÞ;
where r and r are adaptively chosen between0 and 1 to produce the
most significant result. The term um in Utw pertains to the burden
score calculated at cj ¼ wj (j ¼ 1,.,m), and the term ut in Utb per-
tains to the burden scores calculated at cj ¼ bj (j ¼ 1,., m).
Het-SKAT-O13 is a different RE version of SKAT-O:
Het-SKAT-O ¼ ku2m þ ð1 kÞHet-SKAT;
where k is adaptively chosen between 0 and 1 to produce the most
significant result. This is a weighted sum of FE-burden (under the
additivemode of inheritance) and Het-SKATand thus is targeted at
the mean effect of the burden score and the heterogeneity of the
effects of individual variants. As such, Het-SKAT-O will be less
powerful than RE-burden if both themean effects and heterogene-
ity exhibit at the burden-score level and will be less powerful than
RE-SKAT if both the mean effects and heterogeneity exhibit at the
individual-variant level. RE-SKAT-O is more versatile than Het-
SKAT-O in that it can potentially detect mean effects and heteroge-
neity at either the burden-score or the individual-variant level.
For the RE tests, the asymptotic approximations to the distribu-
tions of the test statistics require large K andmight not be accurate
for small K. Lee et al.13 analytically calculated the p values for Het-
SKAT and Het-SKAT-O through modified moment-matching
approximation and numerical integration. More-accurate p values
for these two tests and other RE tests can be obtained through
Monte Carlo simulation.12 To be specific, we repeatedly generate
Uk from the m-variate normal distribution with mean 0 and
covariance matrix Vk for k ¼ 1,., K and recalculate the test statis-
tic. We then set the p value to be the proportion of the simulated
test statistics that aremore significant than the observed test statis-
tics. To improve computational efficiency, we employ an adaptive
procedure that uses a small number of simulations for a large
p value and a large number of simulations for a small p value.
Traditional RE models assume normality of random effects,24
which is an untestable assumption. In the Monte Carlo approach
to calculating p values, however, the normality of random effects
is not used at all. Indeed, the corresponding RE tests will have cor-
rect type I error even if the RE models are completely wrong.
Because the forms of the RE test statistics are determined by the
REmodels, misspecification of the REmodels will affect the power
of the RE tests, although not their validity.e American Journal of Human Genetics 97, 35–53, July 2, 2015 39
Figure 1. The Impact of Transformation on Meta-analysis of Two Studies
The original trait distributions are skewed in both studies such that variance is larger in study 2 than in study 1. After INT, both distri-
butions are normal and have the same variance. After R-INT, both distributions are normal, and the two variances are the same as their
original values. If the effect sizes are originally equal between the two studies, then the effect sizes are unequal after INT but are approx-
imately equal after R-INT.Statistical Efficiency
There are two possible ways to combine the results of multiple
studies: meta-analysis of summary statistics and joint analysis of
individual-participant data. It is logistically difficult and time
consuming to obtain individual-participant data. Indeed, protec-
tion of human subjects and other study policies often prohibit
investigators from releasing individual-participant data. Data
storage and analysis can also be a major challenge for whole-
exome and whole-genome sequencing in a large consortium. A
question naturally arises as to whether there is any loss of statisti-
cal power from combining summary statistics as opposed to
jointly analyzing individual-participant data.
Under FE models,Um is the score statistic for testing the null hy-
pothesis that m ¼ 0 in the joint likelihood based on all individual-
participant data from the K studies under the assumption that the
nuisance parameters g and f are study specific.25 Thus, meta-anal-
ysis is numerically identical to joint analysis under FE models. The
calculation of summary statistics for one study does not involve
data from other studies, so the nuisance parameters are naturally
study specific in meta-analysis. In the joint likelihood, however,
we can assume the nuisance parameters to be the same across
studies and thus reduce the total number of independent parame-
ters. In that case, joint analysis is more efficient than meta-anal-
ysis. However, the efficiency gain is minimal because the nuisance
parameters can be estimated accurately in each study. In addition,
the joint analysis might be biased if the assumption of common
nuisance parameters is violated. Thus, it would be undesirable to
make that assumption anyway.
Het-SKAT and Het-SKAT-O were derived from the joint analysis
of individual-participant data.13 For the other RE tests, we show
in Appendix B that the use of summary statistics is also equivalent
to the use of individual-participant data.40 The American Journal of Human Genetics 97, 35–53, July 2, 2015The equivalence of meta-analysis and joint analysis is predi-
cated on the use of score statistics as the summary statistics. For
quantitative traits, the score statistics should be normalized by re-
sidual variances; otherwise, meta-analysis (although still valid)
will not be as powerful as joint analysis unless residual variances
are the same across studies.
Transformation
We can make residual variances the same across studies by stan-
dardizing the trait values or applying the inverse-normal transfor-
mation (INT) to the trait values in each study. However, the
transformation alters the scale of measurement for the genetic
effects, and the amount of change depends on the original trait
variance. Such transformation tends to reduce the power of
meta-analysis, as explained in Appendix C.
Non-normality of residuals can inflate type I error and reduce
power in association tests. INT is a convenient and effective way
to achieve normality, especially in a consortium. As mentioned
above, however, INT alters the scale of measurement by different
degrees for studies with unequal trait variances and thus reduces
the power of meta-analysis. To address this issue, we multiply
the transformed trait values by the SD of the original trait values
in each study such that the resulting trait variance is the same as
the original trait variance. This strategy, to be called rescaled INT
(R-INT), achieves the best of two worlds: (1) it makes the trait dis-
tributions normal and thus controls the type I error, and (2) it re-
stores the original scale of measurement and thus enhances the
power of meta-analysis. An added benefit is that the effect sizes
pertain to the original measurement and thus are more meaning-
ful. Figure 1 provides a graphical illustration of how R-INT works.
It is easy to show that the score statistic and information matrix
under R-INT are U/S and V/S2, respectively, where U and V are the
score statistic and information matrix, respectively, under INT,
and S is the SD of the original trait values. Thus, the rescaling can
be done after summary statistics have been obtained under INT.
The estimation of SD is sensitive to outlying observations.
A commonly used robust estimator of SD is 1.48263MAD, where
MAD is the medium absolute deviation. We adopt this robust esti-
mator in R-INT because it tends to slightly improve power.Results
Simulation Studies
Various simulation studies have been performed to eval-
uate meta-analysis methods;12–14,17 however, none of
them have included all of the methods described in this
article. Thus, we conducted simulation studies to compare
all of the methods under the same settings. We considered
meta-analysis of six studies with 1,000 unrelated subjects
each. Following Liu et al.,14 we generated 12,000 haplo-
types of length 1,000 kb under a calibrated coalescent
model26 to mimic a sample of three European populations.
The model included an ancient bottleneck, recent expo-
nential growth, differentiation, and migration. For each
simulated dataset, we randomly selected a 5,000-bp region
and removed variants with a MAF > 5%. We generated
quantitative traits under three structures of genetic effects:
(1) the rare-variant model, in which 50% of variants with a
MAF < 0.5% are causal such that each increases the trait
value by the same amount d; (2) the low-frequency-variant
model, in which 50% of all variants are causal such that
each increases the trait value by the same amount d; and
(3) the opposite-effects model, in which 50% of all variants
are causal such that 80% increase the trait value by d, and
the remaining 20% decrease the trait value by d.
We evaluated the meta-analysis methods for the burden,
VT, SKAT, and SKAT-O tests. For the burden and VT tests,
we set the burden score to be the total number of muta-
tions in the gene. In addition, we chose the weights
involved in SKAT and SKAT-O according to the beta(MAFj;
1, 25) function, where MAFj is the j
th variant’s MAF esti-
mated from all study subjects. We used 10,000 replicates
to evaluate power at the nominal significance level of
2.5 3 106 and used 2.5 million replicates to evaluate
type I error at the nominal significance level of 103.
First, we compared the power of ten FE and RE tests
based on normalized score statistics without transforma-
tion: FE-burden, FE-VT, FE-SKAT, and FE-SKAT-O under
FE models; and RE-burden, RE-VT, RE-SKAT, RE-SKAT-O,
Het-SKAT, and Het-SKAT-O under RE models. We set the
error distributions to standard normal in all six studies
and let the effect size d for each study be a normal
random variable with mean m and variance tb. Note that
m represents the mean effect, and tb characterizes the het-
erogeneity. We set m ¼ 0.25 or 0 and varied the value of tb
from 0 to 0.25.
The results for m ¼ 0.25 are shown in Figure 2A. When
the heterogeneity of genetic effects is low, FE-burden and
FE-VT are more powerful than RE-burden and RE-VT,
respectively, whereas FE-SKAT and FE-SKAT-O have powerThsimilar to that of RE-SKAT and RE-SKAT-O, respectively.
When the heterogeneity is strong, all RE tests are substan-
tially more powerful than their FE counterparts. For both
the FE and REmodels, VT is more powerful than other tests
under model 1, whereas SKATand SKAT-O are more power-
ful than burden and VT under model 3. Under models 1
and 2, RE-SKAT-O is more powerful than the other RE VC
tests. Under model 3, Het-SKAT and Het-SKAT-O are sub-
stantially less powerful than RE-SKAT and RE-SKAT-O
when the heterogeneity is low and slightly more powerful
when the heterogeneity is strong.
The results for m ¼ 0 are shown in Figure 2B. The RE tests
start with the same low power as in the FE tests when there
is low heterogeneity and rapidly become more powerful
than the FE tests when heterogeneity gets stronger. RE-
SKAT-O remains more powerful than the other RE VC tests
under models 1 and 2. Het-SKAT and Het-SKAT-O tend to
be more powerful than RE-SKAT and RE-SKAT-O under
model 3.
Next, we compared the performance of normalized and
un-normalized score statistics, as well as INT and R-INT,
when trait variances are potentially different and error dis-
tributions are possibly non-normal. We considered two
error distributions: (1) a normal distribution with mean
0 and variance s2 and (2) a 95%:5%mixture of normal dis-
tribution with mean 0 and variance s2 and normal distri-
bution with mean 4 and variance s2, where the values of
s2 in the six studies follow a log-normal distribution
with mean 1 and SD ¼ 0–0.5. We set the effect size d in
each study to 0.45 under model 1 and to 0.25 under
models 2 and 3. We compared five versions of FE-burden,
FE-VT, and FE-SKAT tests: normalized score statistics
with no transformation, INT, and R-INT and un-normal-
ized score statistics with no transformation and INT. The
results on type I error and power are shown in Table 1
and Figure 3, respectively. We have omitted the results
for un-normalized score statistics with INT because they
are indistinguishable from those of normalized score statis-
tics with INT.
We first comment on the results for normal distribu-
tions, under which normalized score statistics without
transformation are theoretically optimal. All tests had cor-
rect control of type I error. When the trait variances were
equal among studies, all versions of each test had similar
power. When the trait variances were unequal, the test
based on normalized score statistics without transforma-
tion was always more powerful than the other versions.
The use of un-normalized score statistics without transfor-
mation entailed the most severe loss of power, and INT re-
gained some of the power loss. R-INT was almost as power-
ful as normalized score statistics without transformation.
We now comment on the results for non-normal distri-
butions. Without transformation, type I error tended to
be inflated (for VT and SKAT), and power was reduced
(for all tests). Both INT and R-INT provided correct control
of type I error and improved power. R-INTwas always more
powerful than INT.e American Journal of Human Genetics 97, 35–53, July 2, 2015 41
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Figure 2. Power of FE and RE Tests as a Function of the SD of the Effect Size when the Mean Effects of Causal Variants Are Either
0.25 or 0
Under model 1 (rare-variant model), 50% of variants with a MAF < 0.5% are causal such that each increases the trait value by the same
amount. Undermodel 2 (low-frequency-variantmodel), 50% of all variants are causal such that each increases the trait value by the same
amount. Under model 3 (opposite-effects model), 50% of all variants are causal such that 80% increase the trait value by the
same amount, and the remaining 20% decrease the trait value by the same amount. The nominal significance level is 2.5 3 106.Finally, we evaluated the approximation method for
conditional analysis with binary traits. We let G1 and G2
be two SNPs each with a MAF of 0.5 and an LD coefficient
of 0, 0.1, or 0.2, and we varied the value of b1 from 0.5 to
0.5. We generated a total of 1,000 case and 1,000 control
individuals or 500 case and 1,500 control individuals.
Figure S1 displays the type I error at the nominal signifi-
cance level of 2.5 3 106. The type I error appears to be
accurate when b1 is close to 0 and below the nominal level
when jb1j is large.
NHLBI ESP
The NHLBI ESP was designed to identify genetic variants in
all human genomic protein-coding regions that are associ-
ated with heart, lung, and blood diseases. The project
contains fivemajor phenotype groups: low-density lipopro-
tein (LDL), body mass index (BMI), blood pressure (BP),
early-onset myocardial infarction (EOMI), and stroke. In
addition, there is a randomsampleof subjectswhohadmea-
surements on a set of core variables. This sample is referred42 The American Journal of Human Genetics 97, 35–53, July 2, 2015to as the deeply phenotyped reference (DPR). DNA samples
were sequenced on theRocheNimbleGenSeqCapEZorAgi-
lent SureSelect Human All Exon 50 MB at the University of
Washington and the Broad Institute.18,19 The variants were
called jointly at the University of Michigan. We restricted
our attention tomissense, nonsense, and splice-site variants
with a call rate > 90% and MAF < 5%.
We considered LDL the trait of interest and adjusted the
LDL values by medication, age, and gender. We included
several covariates in the linear regression: the top two prin-
cipal components for ancestry, cohorts, and sequencing
targets. Measurements of LDL were available in all six
phenotype groups. For each phenotype group, we treated
the African-American (AA) and European-American (EA)
samples separately. After excluding subjects with sex
mismatch or relatedness, we were left with 296, 526, 214,
351, 75, and 240 AA subjects and 331, 0, 325, 484, 123,
and 700 EA subjects in the LDL, BMI, BP, EOMI, stroke,
and DPR groups, respectively. In order to account for
different sampling designs in the six phenotype groups27
Table 1. Type I Error Divided by the Nominal Significance Level in
the Meta-analysis of Six Studies
Test
Normal Distribution
Mixture-Normal
Distribution
CV ¼ 0 CV ¼ 0.3 CV ¼ 0.5 CV ¼ 0 CV ¼ 0.3 CV ¼ 0.5
Burden 0.98 0.98 0.99 1.01 1.01 1.01
Burden-UN 0.98 0.98 0.97 1.01 1.01 0.99
Burden-INT 0.99 0.98 0.98 1.02 1.02 1.02
Burden-R-
INT
0.99 0.99 0.99 1.03 1.02 1.02
VT 1.01 0.99 1.00 1.06 1.08 1.09
VT-UN 1.01 0.99 1.00 1.06 1.06 1.06
VT-INT 1.02 1.01 1.02 1.03 1.03 1.02
VT-R-INT 1.01 1.00 1.01 1.03 1.03 1.03
SKAT 1.00 0.98 0.99 1.12 1.15 1.15
SKAT-UN 0.99 0.98 0.99 1.13 1.13 1.12
SKAT-INT 0.99 0.97 0.98 1.01 1.02 1.02
SKAT-R-INT 1.00 0.98 0.99 1.02 1.00 0.99
Burden, burden-INT, and burden-R-INT are based on normalized score statis-
tics with no transformation, INT, and R-INT, respectively, and burden-UN is
based on un-normalized score statistics without transformation. VT, VT-UN,
VT-INT, VT-R-INT, SKAT, SKAT-UN, SKAT-INT, and SKAT-R-INT are defined
analogously. CV is the coefficient of variation for the trait variance in the six
studies. The nominal significance level is 0.001.and explore heterogeneity between the AA and EA popula-
tions, we treated the 11 phenotype group 3 race combina-
tions as 11 separate studies. In the meta-analysis, we
obtained the score statistics for the 11 studies from
SCORE-SeqTDS27 and combined them in MASS to produce
gene-level association tests. For the burden tests, we used
the MAF thresholds of 1% and 5%, and the corresponding
tests are called T1 and T5, respectively. The MAFs were
based on all ESP subjects, although race-specific MAFs
could have been used instead.
Table 2 summarizes the results for LDLR (MIM: 606945),
whose common variants were previously identified to be
associated with lipid traits and coronary heart diseases,
and heterogeneous associations among ethnic groups were
reported.28 The p values for normalized score statistics
without transformation were more significant than their
un-normalized counterparts. INT led tomore-significant re-
sults in most cases. With INT, normalized and un-normal-
ized score statistics yieldedvery similar results. R-INTyielded
the most-significant results in virtually all cases. The differ-
ences in p values, however, were not large because the coef-
ficient of variation for the trait variance was only 0.15.
LDLR has 54 rare variants (each with a MAF < 1%), so
T1 and T5 are the same. For both FE-VT and RE-VT,
the maximum of the test statistics occurred at the
MAF threshold of 0.02%, which corresponds to mostly sin-
gletons. The variants with a MAF < 0.02% had similar
effects on LDL, but those with a MAF > 0.02% did not,12
such that compared to other tests, VT yielded more-sig-Thnificant p values. When we collapsed variants with a
MAF < 0.02%, the effects of the burden scores were largely
similar among the 11 studies. When we collapsed variants
with aMAF< 1%, however, the effects of the burden scores
were quite heterogeneous; the heterogeneity was largely
driven by the variability of genetic effects between AA
and EA subjects.12 Thus, FE-VT yielded more-significant re-
sults than did RE-VT, whereas the RE meta-analysis pro-
vided stronger evidence of association than did the FE
meta-analysis for the T1 and SKAT-O tests.
Results from RE-SKAT were slightly less significant than
those from FE-SKAT. The reason is that almost all of the
mutations for each variant were from one race group, so
the heterogeneity between the two races could be fully
captured by FE-SKAT, and RE-SKAT did not gain additional
information.12 By contrast, RE-T1 yielded more-significant
results than did FE-T1 because there was considerable het-
erogeneity at the T1 burden-score level. Het-SKAT and Het-
SKAT-O (based on normalized score statistics without
transformation) had asymptotic p values of 2.9 3 103
and 1.2 3 103, respectively, and Monte Carlo p values
of 6.2 3 103 and 2.8 3 104, respectively; the results
from these tests were less significant than those from RE-
SKAT and RE-SKAT-O.Software
Meta-analysis software for GWASs is not suitable for
sequencing studies because such software performs single-
variant analysis based on Wald statistics rather than gene-
level analysis based on score statistics. In addition, standard
statistical software doesnot produce score statistics or infor-
mation matrices. Thus, meta-analysis software for rare-
variant association tests invokes two major steps: (1)
study-level analysis to generate score statistics and informa-
tion matrices and (2) meta-analysis to combine summary
statistics and perform gene-level association tests. We
describe below four such software packages: MASS,11,12
MetaSKAT,13 RAREMETAL,14,15 and seqMeta.16,17
Table 3 shows the operators of the four software packages
for study-level analysis. For the two stand-aloneCpackages,
MASS and RAREMETAL, study-level analysis is supported
by the accompanying software SCORE-Seq4/SCORE-
SeqTDS27 and RAREMETALWORKER,14 respectively. For
the two R packages, MetaSKAT and seqMeta, study-level
analysis is supported by certain functions in the packages.
MASS, seqMeta, and MetaSKAT support both binary and
quantitative traits, whereas RAREMETAL supports quanti-
tative traits only. seqMeta supports (censored) survival
data and implements a signed likelihood-ratio statistic,
which is asymptotically equivalent to the score statistic.
All four packages handle studies of unrelated subjects;
RAREMETALWORKER and seqMeta also handle family
studies with quantitative traits. SCORE-SeqTDS in MASS
allows trait-dependent sampling. For studies of un-
related subjects, RAREMETALWORKER used to implemente American Journal of Human Genetics 97, 35–53, July 2, 2015 43
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Figure 3. Power of FE Tests as a Function of the Coefficient of Variation of the Trait Variance in Six Studies
Under model 1 (rare-variant model), 50% of variants with a MAF < 0.5% are causal such that each increases the trait value by the same
amount. Under model 2 (low-frequency-variant model), 50% of all variants are causal such that and each increases the trait value by the
same amount. Under model 3 (opposite-effects model), 50% of all variants are causal such that 80% increase the trait value by the same
amount, and the remaining 20% decrease the trait value by the same amount. Burden, burden-INT, and burden-R-INT are based on
normalized score statistics with no transformation, INT, and R-INT, respectively, and burden-UN is based on un-normalized (UN) score
statistics without transformation. VT, VT-UN, VT-INT, VT-R-INT, SKAT, SKAT-UN, SKAT-INT, and SKAT-R-INT are defined analogously.
The nominal significance level is 2.5 3 106. Under normal distributions, the curves for normalized score statistics without transforma-
tion and with R-INT largely overlap. CV, coefficient of variation.un-normalized score statistics, but newer versions have
implemented normalized score statistics; the other three
packages have always implemented normalized score
statistics.
Table 4 lists the meta-analysis methods implemented
in the four software packages. All FE tests have been
implemented in MASS and RAREMETAL. The FE-burden,
FE-SKAT, and FE-SKAT-O tests have been implemented in
MetaSKAT and seqMeta. VT and conditional analyses are
available in MASS and RAREMETAL. For conditional
analysis, MASS implements Equations 3 and 4, whereas
RAREMETALWORKER omits the factor ~s2=bs2, such that
the results are not exact. In addition to providing asymp-
totic p values, MASS provides Monte Carlo p values, which
are more accurate than asymptotic p values for SKAT and
SKAT-O. RE tests are available in MASS and MetaSKAT:
MASS has incorporated all of the RE tests and provides
Monte Carlo p values, whereas MetaSKAT has incorpo-44 The American Journal of Human Genetics 97, 35–53, July 2, 2015rated RE-burden, Het-SKAT, and Het-SKAT-O and provides
asymptotic p values.
Figure 4 shows the meta-analysis pipelines for the four
software packages. Each pipeline consists of two major
steps. First, it inputs individual-participant data and per-
forms study-level analysis to generate relevant summary
statistics. Second, it combines summary statistics across
studies and performs gene-level association tests. All
four pipelines take advantage of the fact that gene-level
association tests can be constructed from variant-level sta-
tistics under the additive mode of inheritance.
In the MASS pipeline, the study-level output from
SCORE-Seq or SCORE-SeqTDS is directly used as input for
MASS. As shown in Figure S2, the MASS pipeline adopts
two strategies to obtain summary statistics for burden
and VT tests. Under the additive mode of inheritance,
MASS uses variant-level summary statistics to construct
burden-score-level statistics. Under the dominant mode
Table 2. The p Values for LDLR in the Meta-analysis of the NHLBI ESP Studies
Model Test
Normalized Score Statistic Un-normalized Score Statistic
Original INT R-INT Original INT
FE T1 6.3 3 103 1.2 3 102 8.6 3 103 8.7 3 103 1.1 3 102
VT 4.6 3 108 1.8 3 108 1.7 3 108 9.1 3 108 2.2 3 108
SKAT 3.0 3 104 1.7 3 104 9.7 3 105 3.6 3 104 1.8 3 104
SKAT-O 6.2 3 104 3.6 3 104 2.0 3 104 7.5 3 104 3.8 3 104
RE T1 5.4 3 105 8.0 3 105 2.7 3 105 1.4 3 104 8.0 3 105
VT 1.0 3 105 8.2 3 106 7.9 3 106 1.8 3 105 8.7 3 106
SKAT 6.4 3 104 3.6 3 104 2.0 3 104 7.2 3 104 3.9 3 104
SKAT-O 7.6 3 105 7.5 3 105 2.7 3 105 1.9 3 104 8.0 3 105of inheritance, MASS reads in the burden-score-level sum-
mary statistics directly. The dominant model is not avail-
able in the other three pipelines.
In theMetaSKATpipeline, study-level analysis is operated
by the function Generate_Meta_Files. This function gener-
ates summary statistics in MSSD and MInfo files from
PLINK-formatted data files (BED, BIM, and FAM), together
with the SNP-set information in a text file.MSSD is a binary
file with between-SNP covariance matrices, and MInfo is a
text file with information on studies and SNP sets.
In the seqMeta pipeline, study-level analysis is operated
by the function prepScores for quantitative and binary
traits, prepCox for survival data, and prepCondScores for
conditional analysis. (Conditional analysis is performed
in individual studies rather than in meta-analysis.) These
functions generate summary statistics in the prepScores
object from R matrices and data frames containing the in-
dividual-participant data and SNP-set information. The
prepScores object is saved as an .RData file and passed on
to a central location.
In the RAREMETAL pipeline, study-level analysis is oper-
ated by the stand-alone software RAREMETALWORKER. It
uses Merlin-formatted input files (PED and DAT) for phe-
notypes29 and VCF files for genotypes.30 The input files
of RAREMETAL are processed in compressed GZIP format.
A major difference between the RAREMETAL pipeline
and the other three pipelines is that RAREMETAL incorpo-
rates the SNP-set information at the meta-analysis stage
rather than at study-level analysis. RAREMETALWORKER
estimates the between-SNP covariance for any two SNPs
that are close on a chromosome. RAREMETAL then con-
verts the sliding-window covariance estimates to the
gene-based covariance matrices by using the SNP-set
grouping file. This strategy allows the analyst in each study
to ignore the grouping of the SNPs and the meta-analyst to
use any gene annotation.
It is important to point out that the formats of the output
files from study-level analysis are not compatible among
the four pipelines. In addition, un-normalized score statis-
tics from older versions of RAREMETALWORKER cannot
be directly combined with normalized score statisticsThfrom the newer versions of RAREMETALWORKER or the
other three operators. Thus, all participating studies are
required to use the same software package. This require-
ment is highly undesirable in a consortium setting. First,
data analysts in different studiesmight prefer different soft-
ware packages. Second, it is not always possible to use one
package for all studies because no package can handle
both family studies and trait-dependent sampling. Third,
summary statistics need to be recalculated whenever inves-
tigators join a new consortium that adopts a different
package.
To remove the aforementioned restriction, we recently
created a program called PreMeta. It converts the format
of any software output file to the format of any other soft-
ware output file and normalizes the score statistics from
older versions of RAREMETALWORKER by the estimated
residual variance. Thus, PreMeta allows the summary
statistics from any operator to be used in any other package
for meta-analysis, as shown in Figure 4. In addition,
PreMeta allows R-INT to be implemented in the meta-
analysis stage by rescaling the score statistics and
information matrices under INT by the SD of the
original trait values. For illustration, we display in Figure 5
the workflow for the meta-analysis of four studies,
in which summary statistics are generated by SCORE-
Seq, RAREMETALWORKER, MetaSKAT, and seqMeta;
PreMeta converts the format of the output files from
RAREMETALWORKER, MetaSKAT, and seqMeta to the
format used in the MASS pipeline and normalizes the score
statistics from RAREMETALWORKER.
The RAREMETAL pipeline is uniquely designed to esti-
mate the covariances for SNPs within sliding windows
in study-level analysis via RAREMETALWORKER. The
sliding-window covariance estimates cannot be derived
from gene-based covariancematrices if SNPs lie in different
genes. Thus, gene-based summary statistics generated by
operators other than RAREMETALWORKER are not infor-
mative enough for recovering the sliding-window sum-
mary statistics required by RAREMETAL. When PreMeta
reformats gene-based summary statistics from other
operators for the RAREMETAL pipeline, the between-SNPe American Journal of Human Genetics 97, 35–53, July 2, 2015 45
Table 3. Operators for Study-Level Analysis in Four Meta-analysis Packages
Study Design Phenotype MASS RAREMETAL MetaSKAT seqMeta
Unrelated subjects binary SCORE-Seq NA Generate_Meta_File prepScores
quantitative SCORE-Seq RAREMETALWORKER Generate_Meta_File prepScores
survival NA NA NA prepCox
Families binary NA NA NA NA
quantitative NA RAREMETALWORKER NA prepScores
Trait-dependent sampling binary SCORE-SeqTDS NA NA NA
quantitative SCORE-SeqTDS NA NA NA
The following abbreviation is used: NA, not applicable.covariance is set to 0 if the two SNPs do not belong to the
same gene. This workaround will produce the correct
covariance information in the meta-analysis if the same
gene annotation is used for generating gene-based sum-
mary statistics and performing meta-analysis (because
the covariances between different genes are not used at
the end).
We have been involved in an exome-sequencing con-
sortium that includes the NHLBI ESP,18,19 CHARGE,31
GOLDN,32 and the Rotterdam Study.33 RAREMETAL was
chosen to perform meta-analysis of rare-variant associa-
tions. However, RAREMETALWORKER does not support
trait-dependent sampling. In the LDL, BMI, and BP pheno-
type groups of the NHLBI ESP, subjects with extreme trait
values were purposely selected for sequencing. Failure to
account for trait-dependent sampling might increase
type I error and reduce power.27 Thus, we used SCORE-
SeqTDS to generate summary statistics for the LDL, BMI,
and BP phenotype groups and used RAREMETALWORKER
for the EOMI, stroke, and DPR phenotype groups. Figure S3
shows the workflow for analyzing the six phenotype
groups. PreMeta is used to rescale the summary statistics
under INTand format the output files from SCORE-SeqTDS
so that RAREMETAL can be used to perform meta-analysis.Table 4. Comparisons of Four Meta-analysis Packages
MASS RAREMETAL MetaSKAT seqMeta
Programming
language
C Cþþ R R
FE tests
implemented
burden, SKAT,
SKAT-O, VT
burden, SKAT,
SKAT-O, VT
burden,
SKAT,
SKAT-O
burden,
SKAT,
SKAT-O
RE tests
implemented
burden, SKAT,
SKAT-O, VT,
Het-SKAT,
Het-SKAT-O
NA burden,
Het-SKAT,
Het-SKAT-O
NA
Conditional
analysis
implemented
yes yes no no
The following abbreviation is used: NA, not applicable.Discussion
Thanks to continuing reduction in sequencing costs,
whole-exome sequencing has now been performed on a
large number of cohorts, and whole-genome sequencing
is increasingly being employed in human genetics
research, notably in the T2D-GENES and UK10K projects.
By combining and contrasting results from multiple
sequencing studies, meta-analysis increases the power to
detect rare variants with modest effects and helps to iden-
tify sources of disagreement among studies.
We have presented a general framework for performing
meta-analysis of rare-variant associations in sequencing
studies. This framework has allowed us to provide a
comprehensive comparison and evaluation of existing sta-
tistical methods and software packages. Specifically, we
have showed the potential loss of power due to the use46 The American Journal of Human Genetics 97, 35–53, July 2, 2015of un-normalized score statistics or the standardization of
trait values. We have discussed the pros and cons of FE
versus RE models. We have described the similarities and
differences among the four software packages.
We have filled some important gaps of knowledge. Spe-
cifically, we have provided a complete treatment of condi-
tional analysis and a thorough investigation of the relative
efficiency of meta-analysis based on summary statistics
versus joint analysis of individual-participant data. We
have proposed R-INT to control type I error and improve
power. In addition, we have developed a software interface
to facilitate the exchange of information among different
meta-analysis packages. This interface allows investigators
in a consortium to generate summary statistics with their
choice of software packages without compromising the
integrity of meta-analysis.
CMC is an extension of the burden test to detect the
joint effects of common and rare variants.5 It divides the
variants into subgroups according to their MAF and col-
lapses the variants within each group. MASS has imple-
mented both the FE and RE versions of such multivariate
burden tests. As an advanced feature of MASS, the user
can customize multiple burden scores by providing a series
of weights for the SNPs within each gene.
Weighting the contributions of rare variants to the
burden score according to their MAF was proposed by
Figure 4. Four Pipelines for Meta-analysis and the Role of PreMeta
Each pipeline inputs individual-participant data, performs study-specific analysis to produce relevant summary statistics, combines sum-
mary statistics across studies, and performs gene-level association tests. PreMeta reformats the files for the summary statistics such that
the information can be exchanged across the four pipelines.Madsen and Browning.2 In their weighted-sum statistic,
the weights are based on the MAFs in the control group,
and the p value is determined by permutation. In the cur-
rent implementation of the MB method, the weights are
based on the MAFs of all subjects, and the p value is calcu-
lated analytically.4,11,14 In the original VT test, the p value
is determined by permutation.6 In the current implemen-
tation, the p value is calculated analytically.4,11,14 Analytic
evaluation of p values not only reduces computing time
but also allows a statistically more efficient way of
combining the results from multiple studies. Indeed, we
combine the summary statistics rather than the p values
of participating studies and calculate the p values only at
the meta-analysis stage.
We focused on quantitative and binary traits for studies
of unrelated subjects and quantitative traits for family
studies. All meta-analysis methods can be applied to
other traits and other designs and be used to combine re-
sults from studies with different designs provided that
the score statistic U and information matrix V can be
calculated for each study. It would be worthwhile to derive
summary statistics for binary traits and survival data in
family studies.
The two meta-analysis packages implemented in C tend
to be faster than the two R packages. MASS provides bothThasymptotic and Monte Carlo p values for FE tests and
Monte Carlo p values for RE tests, whereas the other pack-
ages only provide asymptotic p values. In the default
setting, MASS generates both asymptotic p values for FE
tests and Monte Carlo p values for RE tests, in which case
MASS can be slow if many genes have small p values. To in-
crease speed, we can use the option ‘‘-A’’ to suppress RE
tests in MASS. It took <3 hr on an IBM HS22 machine to
perform eight tests—FE-burden, RE-burden, FE-VT, RE-VT,
FE-SKAT, RE-SKAT, FE-SKAT-O, and RE-SKAT-O—in the
genome-wide analysis of the NHLBI ESP data involving
11 studies and 15,404 genes. In terms of interface,
RAREMETAL optimizes performance by using the PLINK
and VCF formats and the zipped and tabix indexed files.
Sliding-window summary statistics require more space
than do gene-based summary statistics.
As discussed earlier, RAREMETAL provides between-SNP
covariance information for sliding windows. The sliding-
window approach offers greater flexibility for gene annota-
tion and conditional analysis than does the gene-based
approach. We are currently developing a sliding-window
capability for the MASS pipeline. We will provide an
option in SCORE-Seq and SCORE-SeqTDS to output the
covariance estimates for each sliding window and let
MASS convert the sliding-window covariance estimatese American Journal of Human Genetics 97, 35–53, July 2, 2015 47
Figure 5. The Role of PreMeta in the Meta-analysis of Four Studies with Different Operators
SCORE-Seq is used to generate summary statistics for study 1, and the output can be directly used as input for MASS.
RAREMETALWORKER, MetaSKAT, and seqMeta are used to generate summary statistics for the other three studies, and the output files
are reformatted by PreMeta to be input into MASS.to the gene-level covariance matrices by using the SNP-set
grouping file.
Rare-variant association tests are constructed from
multivariate summary statistics, i.e., the score vector U
and information matrix V, which might not be available
in retrospectively designed meta-analysis. Hu et al.20
showed that multivariate statistics can be recovered from
single-variant statistics (i.e., p values of association tests
and effect estimates) from participating studies, together
with the correlation matrix of the single-variant test
statistics, which can be estimated from one of the partici-
pating studies or from a publicly available database.
This approach has been implemented in the software
MAGA,20 which currently performs FE-burden, FE-VT,
and FE-SKAT tests. The reconstructedmultivariate statistics
can potentially be read into other meta-analysis packages
for performing additional tests.
We focused on FE and RE tests, which are as powerful as
joint analysis of individual-participant data. Alternatively,
we can combine p values non-parametrically by using
Fisher’s method or the minimum p value. Without taking
into account the directions of associations or study sizes,
such methods tend to be less powerful than FE and RE
tests.12,14 However, they can be useful if only p values are
available or summary statistics are not compatible (because
of differences in sequencing platform, phenotype defini-
tion, or test statistics).
The software VAT34 features a large collection of utilities
for variant-site and call-level quality control, summary sta-
tistics, phenotype- and genotype-based sample selection,
variant annotation, variant selection for association anal-
ysis, and gene-level association tests. It includes an inter-
face to the SKAT and SCORE-Seq programs and additional
rare-variant association tests. For meta-analysis, it imple-
ments Fisher’s method of combining p values, as well as
the methods used by MetaSKAT. The results of study-level
analysis and meta-analysis are stored and managed within
the project database system.48 The American Journal of Human Genetics 97, 35–53, July 2, 2015In practice, participating studies might use different
sequencing platforms and thus capture different sets of
variants. If a particular variant is not measured in the kth
study, we simply set the corresponding entries in Uk and
Vk to 0. Thus, each study will contribute all the informa-
tion it collects to meta-analysis. In such situations, RE tests
are preferable to FE tests because the association signals are
expected to be highly heterogeneous across studies.
In large cohorts that have been used for GWASs, it is pro-
hibitively expensive to sequence all cohort members, such
that sequencing can only be performed on a subset of
members, usually those with extreme trait values or spe-
cific diseases. By imputing the sequencing data from the
GWAS data for the cohort members who are not selected
for sequencing, we can dramatically increase the number
of subjects with information on rare variants. We can
then perform association tests for rare variants by
combining the observed genotypes for sequenced subjects
and the imputed genotypes for non-sequenced subjects.35
When the sample size is small, the asymptotic approxi-
mation to the score statistics might not be accurate. Chen
et. al17 replaced the score statistics by the signed square-
root likelihood-ratio statistics and showed better control
of type I error. This approach has been implemented in
the seqMeta function preCox. For unbalanced case-control
studies, score statistics tend to be anti-conservative, and the
Firth bias correction has been recommended.36
The aforementioned adjustments might not correctly
control type I error for very rare variants. To obtain exact
p values, we can appeal to permutation and other resam-
pling methods.4 If resampling is indeed used for obtaining
p values in each study, then the results can be combined
by Fisher’s method. A statistically more efficient strategy is
to resample the individual-participant data from all studies.
SCORE-Seq has the option of resampling p values.4
In sum, we have provided a comprehensive overview
of current statistical methods and software programs
for meta-analysis of sequencing studies for detecting
rare-variant associations. With the proliferation of
sequencing studies worldwide, these tools will surely play
an important role in human genetics research over the
coming years.Appendix A: Score Statistics for Conditional
Analysis
The score statistic for testing the null hypothesis that
b2 ¼ 0 takes the form
~U2 ¼ 1
a

~f
 Xn
i¼1
n
Yi  b0

~b
T
1G1i þ ~gTXi
o
G2i;
where ~b1 and ~g are the roots of the following function:
Sðb1;gÞ ¼
Xn
i¼1

Yi  b0
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G1i
Xi

:
By the Taylor series expansion of Sð~b1; ~gÞ at b1 ¼ 0 and
g ¼ bg; we obtain
S

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
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:
Because Sð~b1; ~gÞ ¼ 0; we have
~b1
~g bg

zI1ð0; bgÞSð0; bgÞ:
We partition Sðb1;gÞ and Iðb1;gÞ according to b1 and g
such that
Sðb1;gÞ ¼

S1ðb1;gÞ
S2ðb1;gÞ

and
Iðb1;gÞ ¼
I 11ðb1;gÞ I12ðb1;gÞ
I 21ðb1;gÞ I22ðb1;gÞ

;
respectively. Clearly, S1ð0; bgÞ ¼ aðbfÞU1: By the definition
of bg, we have S2ð0; bgÞ ¼ 0: Denote the inverse of the par-
titioned matrix Iðb1;gÞ as
I1ðb1;gÞ ¼
I11ðb1;gÞ I 12ðb1;gÞ
I21ðb1;gÞ I 22ðb1;gÞ

;
where I11ðb1;gÞ ¼ fI11ðb1;gÞ  I12ðb1;gÞI122 ðb1;gÞ3
I21ðb1;gÞg1; and I21ðb1;gÞ ¼ I122 ðb1;gÞI21ðb1;gÞ3
I11ðb1;gÞ: It is easy to see that I11ð0; bgÞ ¼ faðbfÞV11g1:
Thus,
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: (Equation A1)ThThe Taylor series expansion of U2 at b1 ¼ 0 and g ¼ bg
yields
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The first term on the right side is aðbfÞU2: In light of Equa-
tion A1, the second term becomes"Xn
i¼1
b00
bgTXiG2iGT1i 
(Xn
i¼1
b00
bgTXiG2iXTi
)
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which is aðbfÞV21V111U1: Therefore,
~U2z
a
bf
a

~f
 U2 V21V111U1: (Equation A2)
For notational simplicity, we abbreviate b00ð~bT1G1i þ ~gTXiÞ
and b00ðbgTXiÞ as ~b00i and bb00i , respectively. The covariance
matrix for ~U2 is
~V2 ¼ 1
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:
Replacing ~b
00
i with
bb00i yields the following approximation:
~V2z
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:
(Equation A3)
We abbreviate I ð0; ~gÞ as I . By matrix multiplications, we
can show that the second term inside the curly brackets
of Equation A3 is
"Xn
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bb00iG2iGTi Xni¼1bb00iG2iXTi
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!Xn
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(Equation A4)
The first term on the right side of Equation A4 follows from
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For the first term inside the brackets of Equation A4,
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Because I122 I21I11I12I122 ¼ I122 I21I111 I12I22 ¼ I1223
fI22  ðI22Þ1gI22 ¼ I22  I122 ; the right side of Equa-
tion A5 is V21V111 I12I122 
Pn
i¼1bb00iG2iXTi I22 þPni¼1bb00i3
G2iX
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i I122 : Thus, the right side of Equation A4 is
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which equals
Xn
i¼1
bb00iG2iXTi I122 Xn
i¼1
bb00iXiGT2i þ abfV21V111V12:
Replacing the second term inside the curly brackets of
Equation A3 with the above expression, we obtain
~V2z
a
bf
a

~f
 V22 V21V111V12: (Equation A6)
Equation A2 might be inexact because of the two Taylor
series expansions. If b1 and g in b
00ðbT1G1i þ gTXiÞ were
evaluated at some intermediate values between ~b1 and 0
and between ~g and bg instead of 0 and bg, then this equa-
tion would be exact. Equation A6might be inexact because
of the replacement of ~b
00
i with
bb00i . If b1 is small, then ~b1 will
be close to 0, and ~g will be close to bg, such that Equations
A2 and A6 will be good approximations. For linear regres-
sion, Equations A2 and A6 are exact regardless of the value
of b1 because b
00ðxÞ ¼ 1 for all x. For logistic regression, the
approximations are reasonable because b00ðxÞ ¼ ex=ð1þ exÞ,
which is not sensitive to small perturbation of x.
For linear regression,
~s2 ¼ n1
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n
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T
1G1i þ ð~g bgÞTXio2:50 The American Journal of Human Genetics 97, 35–53, July 2, 2015Given that
Pn
i¼1ðYi  bgTXiÞXi ¼ 0; the second term on
the right side equals 2n1bs2UT1~b1; which becomes
2n1bs2UT1V111U1 in light of Equation A1. It also follows
from Equation A1 that the third term equals
n1bs2UT1V111U1: Hence, ~s2 ¼ bs2ð1 n1UT1V111U1Þ:
Appendix B: Efficiency of RE Tests
Suppose that there are K independent studies and nk sub-
jects in the kth study. The individual-participant data
consist of (Yki, Gki, Xki) (i ¼ 1,., nk; k ¼ 1,., K), where
Yki,Gki, andXki denote the trait, genotypes, and covariates,
respectively, for the ith subject of the kth study. Let ski
denote the burden score derived from Gki.
For the burden and VT tests, the linear predictor takes
the form mski þ xkski þ gTkXki; where xk is a zero-mean
random variable with variance t: The likelihood function
for m, t, and gk (k ¼ 1,., K) is the integration of the
following expression with respect to the distribution func-
tion of (x1,., x

K):
exp
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)
;
where fk is the value of f in the k
th study. Through a two-
term Taylor series expansion,37 we can approximate the
log-likelihood function as
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Thus, the score statistic for testing the null hypothesis that
m ¼ t ¼ 0 consists of
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where bgk and bfk are the restricted MLEs of gk and fk,
respectively, and
Ct ¼ 1
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To correct for the small-sample bias due to estimating gk,
38
we modify Ct as follows:
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It is easy to verify that Sm ¼
PK
k¼1u

k ¼ um and St ¼
ð1=2Þðut  vm Þ:
For SKATand SKAT-O, the linear predictor takes the form
mTGki þ xTkGki þ gTkXki;where m is a zero-mean random vec-
tor with covariance matrix twW, and xk is a zero-mean
random vector with covariance matrix tbB. The likelihood
function for tw, tb, and gk (k ¼ 1,., K) is the integration of
the following expression with respect to the distribution
functions of m and ðx1;.; xKÞ:
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Through a two-term Taylor series expansion,37 we can
approximate the log-likelihood function as
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Thus, the score statistic for testing the null hypothesis that
tw ¼ tb ¼ 0 consists of
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Upon modifying Ctw and Ctb to correct for the small-
sample bias due to estimating gk,
38 we can show that
Stw ¼
1
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 XK
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and
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1
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which are exactly Utw and Utb , respectively.Appendix C: Effects of Transformation on Power of
Association Tests
Suppose that we wish to combine the results of two studies
under the FE model for the burden score: Y1i ¼ a1þ
bs1i þ e1i (study 1) and Y2i ¼ a2 þ bs2i þ e2i (study 2),
where a1 and a2 are study-specific intercepts, b
 is the
common effect of the burden score, and e1i and e2i are
random errors with study-specific variances s21 and s
2
2;
respectively. By dividing the trait values for study 1
and study 2 by s1 and s2, respectively, we obtain
~Y1i ¼ ~a1 þ ~b1s1i þ ~e1i (study 1) and ~Y2i ¼ ~a2 þ ~b

2s2i þ ~e2i
(study 2), where ~b

1 ¼ b=s1, ~b

2 ¼ b=s2, and both ~e1i and
~e2i have the unit variance. Because ~b

1s~b

2 unless s1 ¼ s2,
the FE model no longer holds, and the association test
will lose power. INT has a similar impact on power because
it also standardizes the trait values. If different studies
employ different transformations, e.g., log versus inverse
normal, then power will be compromised to an even
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